The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pharmacological Rescue of Mutant p53 Conformation and Function
Abstract
Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CP31398 administration can recover the transcriptional activity of partial mutant p53 and inhibit the thermal denaturation of wild-type p53 because of its Michael acceptor characteristics.313”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [313]
In the citing paper
“CP31398 was the first compound discovered that can reactivate mutant p53.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [313]
In the citing paper
“For example, CP-31398 was initially thought to maintain the wild-type conformation of the mutant p53,454 but was shown to be unable to bind p53 in a different lab.455”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [454]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Prion Diseases and the BSE Crisis
Prusiner, S. B. (1997) · Science · doi:10.1126/science.278.5336.245 · Cited by 954
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Tumor measurement in the nude mouse
Euhus, D. M., Hudd, C., Laregina, M. C., & Johnson, F. E. (1986) · Journal of Surgical Oncology · doi:10.1002/jso.2930310402 · Cited by 605
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation
Sato, S., Ward, C. L., Krouse, M. E., Wine, J. J., & Kopito, R. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.635 · Cited by 519
Small peptides activate the latent sequence-specific DNA binding function of p53
Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 434
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Stephen, C. W., & Lane, D. P. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90386-x · Cited by 210
Wang, E. H., Friedman, P. N., & Prives, C. (1989) · Cell · doi:10.1016/0092-8674(89)90913-6 · Cited by 207
Wild-type p53 adopts a ‘mutant’-like conformation when bound to DNA.
Halazonetis, T. D., Davis, L. J., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05743.x · Cited by 193
Hainaut, P. L., & Milner, J. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05434.x · Cited by 138
Taubes, G. (1996) · Science · doi:10.1126/science.271.5255.1493 · Cited by 134
Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Ll, N., Dell, J., Maxwell, E., et al. (1997) · PubMed · Cited by 114
Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., & Minna, J. D. (1993) · PubMed · Cited by 114
Milner, J., & Watson, J. V. (1990) · PubMed · Cited by 108
Regulation of Mutant p53 Temperature-sensitive DNA Binding
Friedlander, P. A., Legros, Y., Soussi, T., & Prives, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 95
Legros, Y., Meyer, A., Ory, K., & Soussi, T. (1994) · PubMed · Cited by 76
Rosenfeld, M. R., Meneses, P., Dalmau, J. O., Drobnjak, M., Cordon‐Cardo, C., & Kaplitt, M. G. (1995) · Neurology · doi:10.1212/wnl.45.8.1533 · Cited by 38
Evidence that immunological variants of p53 represent alternative protein conformation
Gamble, J. A., & Milner, J. (1988) · Virology · doi:10.1016/0042-6822(88)90486-2 · Cited by 26
The characterisation of p53 binding phage isolated from phage peptide display libraries
Daniels, D. A., & Lane, D. P. (1994) · Journal of Molecular Biology · doi:10.1016/0022-2836(94)90038-8 · Cited by 25
Cited by
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Metadata
- Authors
- Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F.
- Venue
- Science
- Published
- 1999-12-24
- Volume
- 286
- Issue
- 5449
- Pages
- 2507-2510
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2058769115
- Cited by
- 799
- References
- 25
- FWCI
- 18.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.